Stress relief supplement sales will grow through 2036, led by ashwagandha at 31.5% of the source segment in 2026. Capsules and tablets lead the dosage form segment with a 44.2% share. The market is expected to reach USD 670.1 million by the end of 2026 and USD 1,144.7 million by 2036.